1. Home
  2. Stocks
  3. Jublpharma Share Price

Jubilant Pharmova Share Price

Pharmaceuticals Mid Cap

₹1,238.10 -14.4 (-1.15%)

05 Nov, 2024 17:29

SIP TrendupStart SIP in JUBLPHARMA

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹1,227
  • High
  • ₹1,255
  • 52 Week Low
  • ₹392
  • 52 Week High
  • ₹1,297
  • Open Price₹1,249
  • Previous Close₹1,253
  • Volume337,921

Investment Returns

  • Over 1 Month + 11.34%
  • Over 3 Month + 45.42%
  • Over 6 Month + 80.42%
  • Over 1 Year + 213.68%
SIP Lightning

Smart Investing Starts Here Start SIP with Jubilant Pharmova for Steady Growth!

Jubilant Pharmova Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 33.3
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 19,721
  • P/B Ratio
  • 3.6
  • Average True Range
  • 66.15
  • EPS
  • 2
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 16.37
  • RSI
  • 62.91
  • MFI
  • 49.52

Jubilant Pharmova Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations165.70162.70201.70170.20186.30
Total Income From Operations165.70166.70205.80175.20186.30
P/L Before Interest, Excpt. Items & Tax24.407.6049.606.007.30
P/L Before Exceptional Items & Tax16.600.0041.50-2.300.20
P/L After Tax from Ordinary Activities10.50-10.2032.50-2.40-0.40
Net Profit/Loss For the Period10.50-10.2032.50-2.40-0.40
IndicatorMar 24Mar 23
Revenue From Operations [Gross]755.20774.42
Revenue From Operations [Net]755.20774.42
Total Operating Revenues784.70810.12
Total Revenue888.10948.01
Total Expenses846.40868.67
Profit/Loss Before Tax41.7079.34
Profit/Loss For The Period31.6049.88
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity143.20-65.12
Net Cash Used In Investing Activity-40.3031.07
Net Cash Used in Finance Activity-77.8022.51
Net Inc/Dec In Cash And Equivalent25.10-11.53
Cash And Equivalent End Of Year36.1010.99
IndicatorMar 24Mar 23
Total Share Capital15.9015.93
Total Non-Current Liabilities302.00232.73
Total Current Liabilities315.40361.19
Total Capital And Liabilities2,991.903,008.47
Total Non-Current Assets2,451.302,429.59
Total Current Assets540.60578.88
Total Assets2,991.903,008.47
Indicator20242023
EBIT Margin (%)9.1212.08
Return On Capital Employed (%)2.673.69
Return On Equity (%)1.332.06
Long Term Debt To Equity (%)10.387.20
Book Value/Share (INR)149.34151.57
IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations1,752.301,720.401,746.401,665.201,666.70
Total Income From Operations1,752.301,731.701,758.601,677.101,680.30
P/L Before Interest, Excpt. Items & Tax219.70174.80184.80159.20155.10
P/L Before Exceptional Items & Tax158.70103.80111.8087.9089.00
P/L After Tax from Ordinary Activities102.60481.80-65.2053.3053.10
Net Profit/Loss For the Period102.60481.80-65.2053.3053.10
IndicatorMar 24Mar 23
Revenue From Operations [Gross]6,644.806,219.30
Revenue From Operations [Net]6,644.806,219.30
Total Operating Revenues6,702.906,281.73
Total Revenue6,771.606,320.06
Total Expenses6,456.306,247.71
Profit/Loss Before Tax146.4015.53
Profit/Loss For The Period48.60-77.13
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity971.30660.67
Net Cash Used In Investing Activity-607.90-544.41
Net Cash Used in Finance Activity-432.50-156.68
Net Inc/Dec In Cash And Equivalent-57.5030.10
Cash And Equivalent End Of Year956.401,013.92
IndicatorMar 24Mar 23
Total Share Capital15.8015.91
Total Non-Current Liabilities4,238.403,992.46
Total Current Liabilities1,889.001,772.40
Total Capital And Liabilities11,548.5011,156.65
Total Non-Current Assets7,672.407,394.25
Total Current Assets3,876.103,762.40
Total Assets11,548.5011,156.65
Indicator20242023
EBIT Margin (%)8.764.14
Return On Capital Employed (%)6.082.77
Return On Equity (%)1.41-1.12
Long Term Debt To Equity (%)58.2857.60
Book Value/Share (INR)343.11338.91

Jubilant Pharmova Technicals

EMA & SMA

Current Price
₹1,238.10
-14.4 (-1.15%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,161.52
  • 50 Day
  • ₹1,094.62
  • 100 Day
  • ₹982.91
  • 200 Day
  • ₹835.38

Resistance and Support

1247.58 Pivot Speed
  • R3 1,404.62
  • R2 1,350.63
  • R1 1,301.57
  • S1 1,198.52
  • S2 1,144.53
  • S3 1,095.47

Is Jubilant Pharmova Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jubilant Pharmova Ltd. is a global pharmaceutical company engaged in radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO, and generics. It operates manufacturing facilities across regulated markets, offering innovative solutions in oncology, autoimmune disorders, and various therapeutic areas. Jubilant Pharmova has an operating revenue of Rs. 6,919.70 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 2% needs improvement, ROE of 1% is fair but needs improvement. The company has a debt to equity of 58%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 55% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 58 which is a POOR score indicating inconsistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of A is the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Jubilant Pharmova Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-19 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-02 Quarterly Results
2023-10-27 Quarterly Results
Date Purpose Remarks
2024-08-02 FINAL Rs.5.00 per share(500%)Final Dividend
2023-08-10 FINAL Rs.5.00 per share(500%)Final Dividend
2022-08-12 FINAL Rs.5.00 per share(500%)Final Dividend
2021-08-06 FINAL Rs.5.00 per share(500%)Final Dividend

Jubilant Pharmova F&O

Jubilant Pharmova Shareholding Pattern

50.68%
3.06%
0.64%
17.94%
0%
18.09%
9.59%
  • NSE Symbol
  • JUBLPHARMA
  • BSE Symbol
  • 530019
  • Managing Director
  • Mr. Priyavrat Bhartia
  • ISIN
  • INE700A01033

Jubilant Pharmova FAQs

Jubilant Pharmova share price is ₹1,238 As on 05 November, 2024 | 17:15

The Market Cap of Jubilant Pharmova is ₹19720.6 Cr As on 05 November, 2024 | 17:15

The P/E ratio of Jubilant Pharmova is 33.3 As on 05 November, 2024 | 17:15

The PB ratio of Jubilant Pharmova is 3.6 As on 05 November, 2024 | 17:15

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.